
    
      40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP,
      will be enrolled. Each evaluable subject involved in this study must fulfill all the
      inclusion and exclusion criteria according the subject grouping, each subject will have 3
      visits in this study, as one screening visit, one imaging visit, and one safety evaluation
      visit.

      Safety measurement will be evaluated by medical history, vital signs, physical examinations,
    
  